PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
about
Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formationA biphasic and brain-region selective down-regulation of cyclic adenosine monophosphate concentrations supports object recognition in the ratSoluble adenylyl cyclase controls mitochondria-dependent apoptosis in coronary endothelial cellsIbudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cellsPDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesisInhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells.FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cellsChronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.Glial restricted precursor cell transplant with cyclic adenosine monophosphate improved some autonomic functions but resulted in a reduced graft size after spinal cord contusion injury in rats.A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulationCell growth inhibitory action of an unusual labdane diterpene, 13-epi-sclareol in breast and uterine cancers in vitro.PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner.Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells.AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.Apoptosis of human neutrophils induced by protein phosphatase 1/2A inhibition is caspase-independent and serine protease-dependent.
P2860
Q24650027-C638D021-359D-4E53-99D7-CD83D1EA38E2Q28480922-4C6F67D9-F054-486E-BACB-60115777211CQ28571558-47BB7BFB-782A-4084-8F40-FD6A6656C3C9Q33873538-9C146CCB-970D-4841-9A5E-EE6832F49D7BQ34351924-7DC53DB5-3B6E-42AF-AAD2-6E1313E3A3C1Q35096709-C36EAF26-210D-4494-89CD-C2DB4C22A969Q35312641-0E4DAA58-FF94-4E1C-82E3-49C8208D012DQ35945171-BF94D2D0-1E9D-44A4-8613-C952BAE2011CQ36334968-D860DC7E-E112-4172-B62D-40636393AFA5Q36585748-9C02C86D-3961-47B4-8A8C-6758D6C8FE7AQ37039636-2124CD3B-35E6-43F4-A2D8-685EF7426140Q37129624-971F2EB6-9485-46B2-8590-0A8D8BE45801Q37178775-DE6864F4-766E-4638-B7B9-F91AB849ADA7Q38104404-2BBF0F2D-89DC-4736-90BC-F9CD957C9AB7Q38984735-6F0842CB-72B2-466D-83C7-885B77D2DD43Q39359743-EA826667-73C7-4BE2-B85C-30CF4155C49AQ39821814-6FE92F84-EA02-4C7A-8A7B-36EED291E51CQ39972783-88825835-F9B3-464F-8BA7-37D45F4A79D6Q40105219-50D195B3-8BE8-4400-8922-E13E1E7A5430Q43183443-04B1FDCE-05AA-4787-BDE9-4D9D4CC78220Q43225747-4B823CBA-7342-44CF-8C6A-77B31786B378Q45296438-B10A9D72-0E0F-48B8-80E3-2353C7997429Q47300115-005FEAD4-CD49-4F41-B54A-AADA344E33BAQ51109588-B54A428D-B493-475E-952D-BF9066B25673Q52656382-F1673499-BD52-4FA3-ADDA-ED8775664064Q53577799-F2DDF493-D732-44AD-8A5E-700A6D9E8A65
P2860
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
PDE4 inhibitors activate a mit ...... ted by protein phosphatase 2A.
@en
type
label
PDE4 inhibitors activate a mit ...... ted by protein phosphatase 2A.
@en
prefLabel
PDE4 inhibitors activate a mit ...... ted by protein phosphatase 2A.
@en
P921
P1433
P1476
PDE4 inhibitors activate a mit ...... ated by protein phosphatase 2A
@en
P2093
Eun-Yi Moon
P304
P356
10.1182/BLOOD-2002-10-3208
P407
P50
P577
2003-01-16T00:00:00Z